Human and Chicken Cathelicidin Peptides Block a Porcine Coronavirus While Pig-Derived Peptides Do Not
The human cathelicidin LL-37 and chicken-derived CATH-B1 strongly inhibited porcine epidemic diarrhea virus at non-toxic concentrations by disrupting virus particles, while four pig-derived antimicrobial peptides showed no antiviral effect.
Quick Facts
What This Study Found
LL-37 (human) and CATH-B1 (chicken) cathelicidins significantly reduced PEDV infection of Vero cells at non-toxic concentrations of 5 and 10 µM, effective in both co-incubation (simultaneous) and pre-incubation setups. Transmission electron microscopy revealed that both peptides directly altered virus morphology and caused aggregation of viral particles, reducing infectivity.
Fluorogenic LL-37 was observed entering cells, suggesting a possible immunomodulatory component to its antiviral action. In stark contrast, none of the four porcine cathelicidins (PMAP-36, PMAP-23, PR-39, PG-1) showed any inhibitory effects against PEDV, even at higher concentrations.
Key Numbers
How They Did This
The researchers tested six cathelicidin antimicrobial peptides against GFP-tagged PEDV in Vero cell cultures. Antiviral activity was measured using flow cytometry and fluorescent microscopy in both co-incubation and pre-incubation setups. Peptide entry into cells was tracked using fluorogenic LL-37. Virus morphology changes were visualized with transmission electron microscopy. Cytotoxicity was assessed to ensure peptides were used at non-toxic concentrations.
Why This Research Matters
PEDV causes massive losses in the global pig industry and no effective antiviral treatments exist. This study identifies two cathelicidin peptides that effectively neutralize the virus and reveals their mechanism — direct disruption of viral particles. The surprising finding that pig-derived peptides don't work against a pig virus while human and chicken peptides do raises important questions about host-pathogen co-evolution and could guide development of novel antiviral peptide therapies.
The Bigger Picture
Antimicrobial peptides are increasingly studied as potential antiviral agents, especially against coronaviruses. LL-37 has already shown activity against multiple viruses including influenza and SARS-CoV-2. This study extends that work to a veterinary coronavirus and reveals that the antiviral mechanism involves direct physical disruption of virus particles. The species-specific differences in efficacy also highlight that antimicrobial peptide evolution is shaped by the specific pathogens each species faces.
What This Study Doesn't Tell Us
This is an in vitro study using Vero cells (monkey kidney cells), not pig intestinal cells where PEDV naturally infects. The study does not include in vivo animal experiments, so it is unknown whether LL-37 or CATH-B1 could effectively treat PEDV infection in live pigs. The concentrations effective in cell culture may not be achievable in the pig gut. Additionally, PEDV primarily infects intestinal epithelium, and peptide stability in the GI environment was not assessed.
Questions This Raises
- ?Why did the pig's own cathelicidins fail against PEDV — has the virus evolved to evade its host's innate antimicrobial peptides?
- ?Could LL-37 or CATH-B1 be delivered effectively to the pig intestine where PEDV infects?
- ?Do these cathelicidins show similar efficacy against other coronaviruses, including human ones?
Trust & Context
- Key Stat:
- 5-10 µM Non-toxic concentration at which LL-37 and CATH-B1 significantly reduced PEDV infection in cell culture
- Evidence Grade:
- This is an in vitro laboratory study using cell cultures. While the experimental methods are rigorous (flow cytometry, TEM, fluorescent microscopy), no animal or clinical data is presented, placing this at an early preclinical evidence level.
- Study Age:
- Published in 2024, this is recent work that builds on growing interest in antimicrobial peptides as antiviral agents following the COVID-19 pandemic.
- Original Title:
- Antiviral activity of cathelicidins against porcine epidemic diarrhea virus (PEDV): Mechanisms, and efficacy.
- Published In:
- Virus research, 350, 199496 (2024)
- Authors:
- Pashaie, Fatemeh, Hoornweg, Tabitha E, Bikker, Floris J(3), Veenendaal, Tineke, Broere, Femke, Veldhuizen, Edwin J A
- Database ID:
- RPEP-09044
Evidence Hierarchy
Frequently Asked Questions
What are cathelicidins and why are they interesting as antivirals?
Cathelicidins are natural antimicrobial peptides produced by the immune systems of many animals, including humans. They are part of the body's first line of defense against infections. LL-37, the only cathelicidin in humans, has shown activity against bacteria, fungi, and multiple viruses. Unlike conventional drugs, these peptides can physically disrupt pathogen structures, making it harder for microbes to develop resistance.
Why couldn't the pig's own defense peptides stop a pig virus?
This is one of the study's most intriguing findings. The researchers suggest it may be a result of co-evolution — PEDV has adapted over time to resist the specific antimicrobial peptides that pigs produce, while it remains vulnerable to peptides from other species that it has never encountered. This has important implications for designing antiviral peptide therapies.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-09044APA
Pashaie, Fatemeh; Hoornweg, Tabitha E; Bikker, Floris J; Veenendaal, Tineke; Broere, Femke; Veldhuizen, Edwin J A. (2024). Antiviral activity of cathelicidins against porcine epidemic diarrhea virus (PEDV): Mechanisms, and efficacy.. Virus research, 350, 199496. https://doi.org/10.1016/j.virusres.2024.199496
MLA
Pashaie, Fatemeh, et al. "Antiviral activity of cathelicidins against porcine epidemic diarrhea virus (PEDV): Mechanisms, and efficacy.." Virus research, 2024. https://doi.org/10.1016/j.virusres.2024.199496
RethinkPeptides
RethinkPeptides Research Database. "Antiviral activity of cathelicidins against porcine epidemic..." RPEP-09044. Retrieved from https://rethinkpeptides.com/research/pashaie-2024-antiviral-activity-of-cathelicidins
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.